GSEP
AUTL

Golden State Equity Partners’s Autolus Therapeutics AUTL Stock Holding History

Golden State Equity Partners’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3,900
Closed -$14.2K – 471
2024
Q3 		$14.2K Buy
+3,900
New +$15.6K 0.01% 544
2022
Q1 		$44K Buy
10,555
+50
+0.5% +$210 0.02% 188
2021
Q4 		$55K Buy
+10,505
New +$63K 0.03% 169

Other funds holding AUTL

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Golden State Equity Partners's AUTL Position: Q4 2024 in Review

Golden State Equity Partners sold out of Autolus Therapeutics (AUTL) in Q4 2024, closing a stake of 3,900 shares — an estimated $14.2K sold.

Golden State Equity Partners first reported a position in AUTL in Q4 2021 and held it in 3 quarters. The position peaked at $55K in Q4 2021. 110 funds tracked by Wall St. Rank hold AUTL as of Q4 2024.

  • Golden State Equity Partners reported no remaining Autolus Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Golden State Equity Partners sold 3,900 Autolus Therapeutics shares in Q4 2024, an estimated $14.2K.
  • Golden State Equity Partners first reported a position in Autolus Therapeutics in Q4 2021 and held it in 3 quarters.
  • Golden State Equity Partners's Autolus Therapeutics position peaked at $55K in Q4 2021.
  • 110 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q4 2024.

Based on Golden State Equity Partners's 13F filing for Q4 2024, filed 24 Jan 2025.